Three years after Hospira tried draining the swamp, the gators are now snapping at Ian Read’s heels.

Why do we write this? That’s because Hospira manufacturing problems are plaguing Pfizer (PFE) two years after paying $15 billion for the company. At the time, Hospira was still struggling to correct quality-control issues at various plants, which caused shortages and steady rebukes from regulators. But a year before the deal, a Hospira executive declared “we’ve got the swamp drained” of gators.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy